Mineralys Therapeutics (MLYS) News Today $13.88 -0.04 (-0.29%) Closing price 04:00 PM EasternExtended Trading$13.95 +0.07 (+0.50%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Wellington Management Group LLP Boosts Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Wellington Management Group LLP raised its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 43.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 91,529 shares of the company's stock afteApril 15 at 3:30 AM | marketbeat.comInstitutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returnsApril 12 at 1:20 PM | finance.yahoo.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.6% - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 5.6% - What's Next?April 11, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Time to Sell?Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - What's Next?April 10, 2025 | marketbeat.comADAR1 Capital Management LLC Increases Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)ADAR1 Capital Management LLC lifted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 15.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 841,541 shares of the company's stock after buying an additioApril 9, 2025 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for MLYSApril 8, 2025 | americanbankingnews.comHC Wainwright Analysts Boost Earnings Estimates for MLYSMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Mineralys Therapeutics in a research report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings peApril 8, 2025 | marketbeat.comPrudential Financial Inc. Acquires 58,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Prudential Financial Inc. grew its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 85.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,650 shares of the companyApril 7, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 55,771 SharesMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 55,771 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $15.76, for a total transaction of $878,950.96. Following the transaction, the insider now owns 116,704 shares in the company, valued at approximately $1,839,255.04. This trade represents a 32.34 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.April 5, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Expected to Rise, HC Wainwright Analyst SaysApril 5, 2025 | americanbankingnews.comMineralys Therapeutics (NASDAQ:MLYS) Sees Unusually-High Trading Volume After Analyst UpgradeMineralys Therapeutics (NASDAQ:MLYS) Sees Unusually-High Trading Volume After Analyst UpgradeApril 4, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Mineralys Therapeutics (NASDAQ:MLYS) Stock PriceHC Wainwright boosted their price objective on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday.April 4, 2025 | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells 55,771 Shares of StockApril 4, 2025 | insidertrades.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by American Century Companies Inc.American Century Companies Inc. reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 848,630 shares of the company's stockApril 4, 2025 | marketbeat.comMineralys Therapeutics price target raised to $42 from $30 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Here's What HappenedMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Still a Buy?April 2, 2025 | marketbeat.comBuy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market PotentialApril 2, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 2.2% - Still a Buy?Mineralys Therapeutics (NASDAQ:MLYS) Shares Up 2.2% - Here's What HappenedApril 1, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)March 31, 2025 | markets.businessinsider.comNEOS Investment Management LLC Sells 33,969 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)NEOS Investment Management LLC cut its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 27.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 89,529 shares of the companyMarch 31, 2025 | marketbeat.comMineralys Therapeutics presents results from Phase 2 Advance-HTN trialMarch 31, 2025 | markets.businessinsider.comPromising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys TherapeuticsMarch 30, 2025 | tipranks.comMineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)March 29, 2025 | globenewswire.comMineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment ProgressMarch 27, 2025 | msn.comMineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke LaffinMarch 27, 2025 | nasdaq.comProficio Capital Partners LLC Invests $285,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Proficio Capital Partners LLC purchased a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,192 shares of the company's stock, valuedMarch 27, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Should You Buy?Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Time to Buy?March 26, 2025 | marketbeat.comInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26, 2025 | 247wallst.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.5% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.5% - Should You Sell?March 25, 2025 | marketbeat.comMineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | insidermonkey.comMineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ETMarch 25, 2025 | globenewswire.comBuy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety ProfileMarch 20, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 7.9% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Up 7.9% - Time to Buy?March 20, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month High - Still a Buy?Mineralys Therapeutics (NASDAQ:MLYS) Sets New 12-Month High - What's Next?March 20, 2025 | marketbeat.comMineralys Therapeutics to Present Phase 2 Trial Data on Lorundrostat for Uncontrolled Hypertension at ACC.25March 19, 2025 | nasdaq.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Insider Buying ActivityMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume Following Insider Buying ActivityMarch 19, 2025 | marketbeat.comMineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25March 19, 2025 | msn.comInsider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Major Shareholder Purchases 600,000 Shares of StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) major shareholder Samsara Biocapital Gp, Llc bought 600,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was bought at an average price of $13.50 per share, with a total value of $8,100,000.00. Following the acquisition, the insider now owns 5,674,916 shares in the company, valued at approximately $76,611,366. This represents a 11.82 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.March 18, 2025 | marketbeat.comInsider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Buys 1,296,296 Shares of StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Ra Capital Management, L.P. purchased 1,296,296 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $13.50 per share, for a total transaction of $17,499,996.00. Following the completion of the purchase, the director now owns 4,280,051 shares of the company's stock, valued at approximately $57,780,688.50. This trade represents a 43.45 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 18, 2025 | marketbeat.comIs Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?March 18, 2025 | insidermonkey.comMineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common StockMarch 18, 2025 | markets.businessinsider.comMineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common StockMarch 18, 2025 | globenewswire.comSamsara Biocapital Gp, Llc Acquires 600,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMarch 18, 2025 | insidertrades.comMineralys Therapeutics announces data from Phase 2 Advance-HTN trialMarch 17, 2025 | markets.businessinsider.comMineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & ExpoMarch 17, 2025 | globenewswire.comMineralys Therapeutics (NASDAQ:MLYS) Trading Up 3.4% - Here's What HappenedMineralys Therapeutics (NASDAQ:MLYS) Trading Up 3.4% - Here's WhyMarch 14, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's What HappenedMarch 13, 2025 | marketbeat.comMineralys Reports Positive Results for Hypertension Drug LorundrostatMarch 13, 2025 | msn.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 9.5% - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 9.5% - What's Next?March 12, 2025 | marketbeat.comMineralys Therapeutics prices $175M stock offeringMarch 12, 2025 | msn.com Remove Ads Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼1.060.80▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼84▲MLYS Articles Average Week Remove Ads Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RARE News Today AKRO News Today MOR News Today SWTX News Today PTGX News Today CPRX News Today MRUS News Today ALVO News Today APLS News Today SRRK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLYS Stock Free MLYS Stock Alerts